Preterm Birth and PROM Testing Market
Preterm Birth and PROM Testing Market 2025 to 2035
The global Preterm Birth and PROM Testing Market is projected to witness significant growth, driven by increasing preterm birth rates and advancements in diagnostic testing. In 2025, the market is estimated to be valued at USD 2.9 Billion, up from USD 2.8 Billion in 2024. With a 4.2% CAGR, the market is anticipated to reach approximately USD 3.6 Billion by 2035.
Market Overview
Preterm birth and Premature Rupture of Membranes (PROM) testing play a crucial role in maternal healthcare, ensuring early diagnosis and management to reduce complications. With over 15 million preterm births annually, accounting for nearly 1 in 10 births worldwide, the demand for advanced and accurate testing solutions is on the rise.
Market Growth Drivers
- Rising Preterm Birth Rates – The prevalence of preterm births is increasing due to higher maternal age, fertility treatments, and multiple pregnancies.
- Technological Advancements – Introduction of rapid POC (Point-of-Care) testing methods like biochemical markers, fetal fibronectin (fFN) testing, and ultrasound-based diagnostics are enhancing early detection.
- Growing Awareness & Government Initiatives – Governments and healthcare agencies are focusing on reducing neonatal mortality through better diagnostic infrastructure.
- Increasing Focus on Women’s Health – The push for preventive healthcare and early-stage diagnosis is further fueling market demand.
Market Restraining Factors
- High Cost of Advanced Diagnostic Testing – Some regions, particularly low-income countries, struggle with affordability and accessibility.
- Limited Awareness & Accessibility in Developing Regions – Despite technological progress, the availability of advanced diagnostic tools remains a challenge in certain areas.
- Regulatory Hurdles – Stringent approvals for new diagnostic tests can delay market expansion.
Key Market Segmentation
| Segment |
Key Insights |
|---|---|
|
By Test Type |
Biochemical Markers, Ultrasound, Pelvic Exam, Uterine Monitoring, Nitazine Test, Ferning Test, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN) |
|
By End Users |
Hospitals, Diagnostic Centers, Homecare Settings, Specialty Clinics |
|
By Region |
North America, Latin America, Europe, Asia-Pacific, Middle East & Africa |
Regional Insights
- North America – Leading the market with a projected valuation of USD 1.1 Billion by 2035, driven by advanced healthcare facilities and rising cases of preterm births.
- Europe – Expected to witness a CAGR of 4.0%, supported by technological advancements in prenatal care.
- Asia-Pacific – The fastest-growing region, anticipated to grow at 5.1% CAGR, owing to increasing healthcare investments and awareness campaigns.
Key Industry Players
- Qiagen N.V.
- Cooper Surgical Inc.
- Hologic
- Abbott
- Biosynex
- Medixbiochemica
- Sera Prognostics
- IQ Products
- Creative Diagnostics
- Bioserv Diagnostic GmbH
Frequently Asked Questions (FAQs)
- What is the growth rate of the Preterm Birth and PROM Testing Market?
- The market is expected to grow at 4.2% CAGR from 2025 to 2035.
- Which segment dominates the market?
- Ultrasound-based testing holds the largest market share due to its non-invasive and high-accuracy nature.
- Which region has the highest demand?
- North America dominates, while Asia-Pacific is the fastest-growing region.
- How does POC testing impact the market?
- Point-of-Care diagnostics are improving accessibility, particularly in remote regions, making testing quicker and more effective.
Competitive Landscape
Companies in this market are focused on enhancing diagnostic accuracy, affordability, and accessibility. Innovation in portable and AI-driven diagnostic tools is expected to revolutionize preterm birth detection.
Contact our advisory for insights on established and emerging players.
Take Action Now!
Unlock the full market potential. Contact us today to access the comprehensive report and propel your business forward!